Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
WITHDRAWN
NCT05532020
PHASE2

An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

Sponsor: Soleno Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a phase 2 open-label, one-arm, clinical study to evaluate the efficacy and safety of DCCR (diazoxide choline) extended-release tablets over 1 year of treatment, in patients with genetic obesities.

Official title: An Open-Label Study to Assess the Preliminary Efficacy and Safety of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Genetic Obesities

Key Details

Gender

All

Age Range

5 Years - Any

Study Type

INTERVENTIONAL

Enrollment

0

Start Date

2023-01

Completion Date

2024-03

Last Updated

2026-10-13

Healthy Volunteers

No

Interventions

DRUG

DCCR (diazoxide choline) extended-release tablets

All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.